Uncovering cutting edge science in the field of immunology




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Uncovering cutting edge science in the field of immunology
Released on: January 23, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    As unmet patient needs persist in the field of immunology, J&J seek out the next-generation treatments to improve the standard of care.
  • Summary
  • Transcript
  • Participants
  • Company
As unmet patient needs persist in the field of immunology, J&J seek out the next-generation treatments to improve the standard of care. Supporting these efforts, our extensive biomarker discovery program compiles valuable information that may ultimately provide health care professionals with the tools needed to consistently prescribe the most appropriate treatment to each patient—the first time. Through cutting-edge technologies, our scientists are able to track disease progression and treatment efficacy in pre-clinical studies, providing us with a better understanding of disease mechanisms, longer-term disease impact and the effect of therapy. Computer-based research also offers insight into disease pathogenesis and potential targets for therapeutic intervention, thus accelerating efforts to bring medicines to market. As unmet patient needs persist in the field of immunology, J&J seek out the next-generation treatments to improve the standard of care. Their focus on understanding disease at the molecular level is key to the discovery of new targets that drive inflammation and autoimmune processes, and their early work on understanding disease triggers may enable entirely new approaches to treating and potentially preventing disease. Susan B. Dillon, Ph.D. Global Therapeutic Area Head, Immunology, Janssen Research & Development, LLC talks to PharmaVentures’ Dr Fintan Walton and explains how they work with the Innovation Centres to get access to science at the earliest stages.
As unmet patient needs persist in the field of immunology, J&J seek out the next-generation treatments to improve the standard of care. Their focus on understanding disease at the molecular level is key to the discovery of new targets that drive inflammation and autoimmune processes, and their early work on understanding disease triggers may enable entirely new approaches to treating and potentially preventing disease. Susan B. Dillon, Ph.D. Global Therapeutic Area Head, Immunology, Janssen Research & Development, LLC talks to PharmaVentures’ Dr Fintan Walton and explains how they work with the Innovation Centres to get access to science at the earliest stages.
Susan B. Dillon, Ph.D
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development brings together the capabilities, culture and people representing our legacy organizations in virology, small molecules and biotechnology. We share an overarching mission: to address and solve the most important unmet medical needs of our time. As Janssen R&D, we work together to harness our combined knowledge and resources, leverage the power and promise of outstanding science, and enhance the length and quality of life for people throughout the world. More than a half century ago, Dr. Paul Janssen established Janssen Pharmaceutica, N.V., a pharmaceutical research laboratory based in Beerse, Belgium. Dr. Paul, as he was known throughout the global scientific community, was a gifted and passionate scientist who refused to accept that there are limits to science and had an unceasing willingness to consider new approaches. Janssen Pharmaceutica became part of the Johnson & Johnson family of companies in 1961. In time, other innovative companies led by other brilliant researchers and entrepreneurs joined the Johnson & Johnson family of companies: in 1999, Johnson & Johnson acquired, Centocor, Inc. (now known as Janssen Biotech, Inc.), a leader in monoclonal antibody technology and acute vascular care and immunology products, in one of the largest biotech deals at the time and in 2002, Tibotec, Inc., a company dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases, joined the Johnson & Johnson family of companies. The spirit of innovation, and the belief that science done well can benefit humanity, has been an integral part of the last 50 years of pharmaceuticals within the Johnson & Johnson family of companies and continues to live on at the Janssen companies. Today, we have thousands of committed employees in many innovative companies located around the world. We are focused on developing novel treatments in five major therapeutic areas: neuroscience, infectious diseases and vaccines, oncology, immunology and cardiovascular/metabolism.